Urologists debunk common prostate cancer myths about age, symptoms, PSA testing and treatment.

Veracyte’s core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins.

A blood test taken years before cancer appears may hold a warning sign for men’s long-term health.

After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator ...

Veracyte is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence. Click here to read more ...

In "Beyond Diagnosis: Metastatic Castration-Sensitive Prostate Cancer," Cleveland Clinic oncologist Christopher Wee, MD, and ...

The NHS is inviting 500,000 men with prostate cancer histories to join Prostate Progress, a research programme focused on ...

Veracyte (NASDAQ:VCYT) reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD ...

Earnings call Veracyte delivered a milestone Q2 2026 with total revenue of $150.3M, up 15% YoY, and adjusted EBITDA of $44M (29.2% margin). Management raised full-year revenue guidance to $590–$596M ...

Veracyte swung to GAAP profitability while crushing EPS estimates by 25% in Q2, powered by 20% growth in Decipher Prostate ...

Grew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19%year-over-year, ...

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap ...